News

The company submitted the application in August this year seeking approval for the initiation of Phase I clinical trial of KB408. The regulator, after the 30-day review of

With an area of around 7,000m2, the new location features the XBCM2 dual-function facility for bioconjugate drug substance and antibody intermediates production. It also comprises the XDP2 facility,

Cabotegravir is indicated for use in high-risk adults and adolescents aged a minimum of 12 years weighing at least 35 kg. It is claimed to be the first

KT-333 is a highly selective degrader of STAT3, a transcriptional regulator that is linked to inflammatory and autoimmune diseases as well as various cancers. The company is also

A Final Draft Guidance (FDG) has been issued for QUVIVIQ for the treatment of these patients with symptoms lasting for three nights or more per week for at

Through the collaboration, BeiGene can access Nona’s fully human transgenic mice platform, Harbour Mice. In 2018, BeiGene received the rights to leverage the Harbour Mice heavy chain (H2L2)

Under the agreement, Synaffix will be eligible for an upfront payment, milestone payments along with tiered royalties on net sales of resulting products. The company will also produce

Under the partnership, the companies will reveal the drug candidate’s mechanism of action as well as pharmacological characterisation. Salipro Biotech CEO Jens Frauenfeld said: “We are excited to

As per the agreement terms, Orbit will discover peptide leads specific to targets related to certain tumours by deploying its bead-based peptide display engine. Orbit Discovery CEO Dr